Physician profile
Niran Jan Amar
NPI 1003812595
$6,183.89
in general payments reported to CMS, 2019-2025
60 companies · $769 in 2025
The $769 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $532 · 2021: $943 · 2022: $1,077 · 2023: $641 · 2024: $670 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.30 |
| Education | $132.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $547.56 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $513.64 | 2019-2025 | Hizentra, Privigen, Haegarda |
| Novo Nordisk INC | $441.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $308.69 | 2019-2025 | Airsupra, Tezspire |
| Genzyme Corporation | $276.44 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $273.41 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Regeneron Healthcare Solutions, INC. | $258.61 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $249.56 | 2019-2025 | |
| Octapharma USA, INC. | $221.17 | 2021-2022 | |
| Jubilant Hollisterstier LLC | $193.46 | 2024 | |
| Blueprint Medicines Corporation | $180.24 | 2023-2025 | Ayvakit |
| Dexcom, INC. | $169.61 | 2019-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.42 | 2019-2021 | |
| Radius Health, INC. | $159.37 | 2023-2025 | Tymlos |
| Mylan Specialty L.P. | $154.77 | 2019-2022 |
Show all 57 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niran Amar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.